Clinical Trial Update: Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating carboplatin, temozolomide, and filgrastim for newly diagnosed or recurrent high-grade glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Filgrastim (filgrastim)
• Temozolomide (Temozolomide)

Snippet

Sponsor: NYU Langone Health | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: WITHDRAWN